PHARMA MAJOR DR.REDDY’S LAB LAUNCHES ICOSAPENT ETHYL CAPSULES IN US MARKET

Highlights
• Dr. Reddy’s is looking to capitalize on the US market as the country has several number of young adults suffering from obesity
• The impact of this launch was immediately visible on the share price of Dr. Reddy’s Laboratories as the company lost 0.34% to Rs 5,261.50 on BSE

According to an announcement made by the pharmaceutical company Dr. Reddy’s Lab, it has launched icosapent ethyl capsules, 1 gram in the US market.
The United States Food and Drug Administration (USFDA) gave an approval to this product by the Indian pharma major used to bring down triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
With this product, Dr. Reddy’s is looking to capitalize on the US market as the country has several number of young adults suffering from obesity.
This new icosapent ethyl by Dr. Reddy’s will be available in 1 gram capsules and sold in the bottle with count size of 120 said the company.
The impact of this launch was immediately visible on the share price of Dr. Reddy’s Laboratories as the company lost 0.34% to Rs 5,261.50 on BSE.

Leave a Reply

Your email address will not be published. Required fields are marked *